Lauren Patterson Cobb

Lauren Patterson Cobb

Auto-generated profile, based on publicly available information

Lauren Patterson Cobb

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2016 in Gynecologic Oncology
Verified
Journal Article
Closed access
EWEmily S. Wu
Emily S. Wu
TOTitilope Oduyebo
Titilope Oduyebo
LCLauren P. Cobb
Lauren P. Cobb
DCDiana Cholakian
Diana Cholakian
XKXiangrong Kong
Xiangrong Kong
KRKara Long Roche
Kara Long Roche

30 March 2022 in Gynecologic Oncology
Verified
Journal Article
Closed access
DGDavid M. Gershenson
David M. Gershenson
CSCharlotte C. Sun
Charlotte C. Sun
SWShannon N. Westin
Shannon N. Westin
MEMostafa Eyada
Mostafa Eyada
LCLauren P. Cobb
Lauren P. Cobb
KWKwong-Kwok Wong
Kwong-Kwok Wong

1 September 2020 in Gynecologic Oncology
Verified
Journal Article
Closed access
LCLauren P. Cobb
Lauren P. Cobb
CSCharlotte C. Sun
Charlotte C. Sun
RIRevathy Iyer
Revathy Iyer
ANAlpa M. Nick
Alpa M. Nick
NFNicole D. Fleming
Nicole D. Fleming
DGDavid M. Gershenson
David M. Gershenson

12 May 2015 in Gynecologic Oncology Research and Practice
Verified
Journal Article
Open access
PDF file
LCLauren Patterson Cobb
Lauren Patterson Cobb
SGStephanie Gaillard
Stephanie Gaillard
YWYihong Wang
Yihong Wang
ISIe-Ming Shih
Ie-Ming Shih
ASAngeles Alvarez Secord
Angeles Alvarez Secord
Traditionally, epithelial ovarian, tubal, and peritoneal cancers have been viewed as separate entities with disparate origins, pathogenesis, clinical features, and outcomes. Additionally, previous classification systems for ovarian cancer have proposed two primary histologic groups that encompass the standard histologic subtypes. Recent data suggest that these groupings no longer accurately reflect our knowledge surrounding these cancers. In this review, we propose that epithelial ovarian, tubal, and peritoneal carcinomas represent a spectrum of disease that originates in the Mullerian compartment. We will discuss the incidence, classification, origin, molecular determinants, and pathologic analysis of these cancers that support the conclusion they should be collectively referred to as adenocarcinomas of Mullerian origin. As our understanding of the molecular and pathologic profiling of adenocarcinomas of Mullerian origin advances, we anticipate treatment paradigms will shift towards genomic driven therapeutic interventions.

1 December 2018 in Hematology/Oncology Clinics of North America
Verified
Journal Article
Closed access
LCLauren P. Cobb
Lauren P. Cobb
DGDavid M. Gershenson
David M. Gershenson

16 March 2023 in International Journal of Gynecological Cancer
Verified
Journal Article
Open access
PDF file
LCLauren Cobb
Lauren Cobb
DGDavid Gershenson
David Gershenson
Low-grade serous ovarian cancer is a rare subtype of epithelial ovarian cancer clinically characterized by younger age at diagnosis, relative chemoresistance, and prolonged survival compared with its high-grade serous counterpart. It is molecularly characterized by estrogen and progesterone receptor positivity, aberrations in the MAPK (mitogen-activated protein kinase) pathway, and wild-type TP53 expression pattern. As research into low-grade serous ovarian cancer as a distinct entity has been able to accelerate independently, we have learned more about its unique pathogenesis, oncogenic drivers, and opportunities for novel therapeutics. In the primary setting, cytoreductive surgery in combination with platinum-based chemotherapy remain the standard of care. However, low-grade serous ovarian cancer has demonstrated relative chemoresistance in the primary and recurrent settings. Endocrine therapy is also commonly utilized in the maintenance and recurrent settings and is being evaluated in the adjuvant setting. Given the many similarities of low-grade serous ovarian cancer to luminal breast cancer, many recent studies have utilized similar therapeutic strategies including endocrine therapy combinations with CDK (cyclin-dependent kinase) 4/6 inhibitors. Additionally, recent trials have investigated combination therapies targeting the MAPK pathway, including MEK (mitogen-activated protein kinase kinase), BRAF (v-raf murine sarcoma viral oncogene homolog B1), FAK (focal adhesion kinase), and PI3K (phosphatidylinositol 3-kinase) inhibition. In this review, we will outline these novel therapeutic strategies for low-grade serous ovarian cancer.